FDA Approves Daratumumab Triplet Combo for Relapsed/Refractory Multiple Myeloma
December 2nd 2021The combination of daratumumab with hyaluronidase (Darzalex Faspro), hyaluronidase-fihj, carfilzomib (Kyprolis), and dexamethasone is indicated for the treatment of adult patients with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy.
Read More
Certain Patients With Heart Failure May Benefit From Stem Cell Therapy
December 1st 2021Stem cell therapy was associated with a reduction of the number of heart attacks, strokes, and death among people with chronic, high-risk, NYHA class 2 or 3 heart failure with reduced ejection fraction (HFrEF), according to a study presented at the American Heart Association’s Scientific Sessions 2021.
Read More